Long COVID Research Pipeline
This page shows what publicly available data tells us about the current state of research into Long COVID, from NIH funding through to clinical trial activity. Data is sourced from public government registries and updated nightly.
NIH Total Funding
Phase 3 Trials
What the data suggests
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a very large amount of public research funding has been directed toward Long COVID in the United States. However, the direction of that funding is falling year on year, which may signal a shift in institutional priorities. For patients, this pattern is worth watching, as the overall level of investment has been substantial, but a continuing decline could affect how many new studies are initiated in the coming period.
Registry data shows activity across both early and late stage clinical trials, which is an encouraging sign for the field. Early stage trials, such as Phase 1 and Phase 2 work, typically focus on safety and initial effectiveness, while later stage trials work toward the kind of evidence needed for regulatory approval. The presence of trials at multiple stages suggests that Long COVID research has moved beyond its earliest steps, though it is not yet at the point where approved treatments are widely available.
For Australian patients, the current picture offers limited near-term certainty. No TGA approval for a Long COVID specific treatment is currently recorded, and no PBS listing has been recorded, meaning no treatment has yet cleared the formal pathways that would make it officially available and subsidised in Australia. No patent activity has been recorded either, which can sometimes indicate that commercially developed treatments are not yet close to market. Patients are encouraged to speak with their treating doctor about what options may exist within current clinical care.
This information is sourced from publicly available government registries and is updated regularly. Always discuss treatment options with your doctor.
Data sourced from NIH Reporter, ClinicalTrials.gov, openFDA, and other public government registries. Updated nightly. This page does not constitute medical advice. Pipeline signals are indicators based on publicly available data, not predictions of clinical outcomes or regulatory decisions.